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issued by CDR, 143 were negative and INESSS agreed with CDR in 90% of these 
recommendations. 132 of CDR’s recommendations were negative, of which INESSS 
agreed in 48% of cases. ConClusions: INESSS has a higher positive recommen-
dation rate and, possibly due to the broader scope for funding recommendations, 
frequently disagrees with CDR’s analysis, particularly when CDR’s recommenda-
tion is negative.
PHP109
InternatIonal Hta referencIng – a realIty?
Sealey S.1, Edathodu A.1, Mukku S.R.2
1Access Partnership, London, UK, 2The Access Partnership, London, UK
objeCtives: Countries already have a long history of referencing each other on 
drug prices through International price Referencing. However it is still unclear 
whether a similar kind of referencing exists for overall market access decisions. 
The objective of this report is 3 fold: first to identify if decision referencing exists 
between these countries and if yes how. Secondly to understand the extent of 
influence one country might have over another, and thirdly whether this process 
is formal or informal. Methods: The research was conducted through in-depth 
secondary research and interviews with stakeholders in 14 countries including the 
UK, Ireland, Germany, France, Spain, Portugal, Italy, Sweden, Canada, Australia, The 
Netherlands, Austria, Hungary and Poland Results: NICE (UK), SMC (Scotland), 
and AWMSG (Wales) represent the more sophisticated attempts to integrate HTA 
into the decision-making process and are currently the most influential HTAs in 
the world with over 60 countries referencing them worldwide. IQWiG (Germany), 
HAS (France), TLV (Sweden), and HSE (Ireland) form the medium influence HTA 
agencies. This can be attributed to the fact that these agencies have their own 
unique approach to HTA. These agencies consider clinical effectiveness and 
comparator studies over cost effectiveness models. Poland, Spain, Italy, Austria, 
Hungary, and Portugal form the low influence HTA agencies that capitalize on the 
lessons learned from more established international HTA systems due to lack of 
in-house qualified personnel and resources for HTA activities. ConClusions: The 
research indicated that there is definitely a cross-influence influence of market 
access decisions between countries across geographies. Decisions are referenced 
informally, via direct contact with other HTA agencies, through international net-
working platforms like EUnetHTA, and INAHTA, or accessing published assess-
ment reports. Variance in the level of influence can be attributed to the age and 
maturity of the HTA, and longevity of assessment performed (specifically cost-
effectiveness assessment).
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PHarmacoeconomIc educatIon In BrazIlIan ScHoolS of PHarmacy
Freitas G., Balbinotto G.
Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil
objeCtives: The Pharmacoeconomics allows economic evaluation of products and 
services for health and helps a lot the health care decision-making. Therefore, there 
is a need for training of human resources with solid knowledge in pharmacoeco-
nomics in Brazil. However, little is known to what extent Pharmacoeconomics is 
taught in schools of pharmacy in Brazil. The objective of this study was to survey the 
pharmacy schools in Brazil to determine the extent of education in pharmacoeco-
nomics offered during the school year 2012-2013. Methods: A questionnaire based 
on previous studies [Rascati (1998, 2005, 2013) was developed. This was emailed to 
55 pharmacy schools in Brazil during October and December 2013. The schools were 
selected from the Ministry of Education website. University schools of public and pri-
vate (only those that have high concepts in the National Examination Performance 
of Students) were included. In addition, a search was made in the database direc-
tories of research groups from National Council for Scientific and Technological 
Development (CNPq). Results: Results of the questionnaires sent 55, 14 went 
unanswered. Only one school does not address the teaching of Pharmacoeconomics 
in no time. Most discuss some concepts within various disciplines (see 8:0). Four 
schools have formal disciplines that teach only Pharmacoeconomics or health 
technology assessment (more than 30 hours). All agree that the education of 
pharmacoeconomics is important. In the search for directories of research groups 
were found 23 groups that develop research in the area of Pharmacoeconomics in 
Brazil. ConClusions: Pharmacoeconomics education in Brazil is still in its infancy 
and there is a unique opportunity for well-trained instructors and researchers to 
fill this gap. Provide an education in Pharmacoeconomics to pharmacy and econo-
mists students is especially important in the context of evidence-based decisions 
and when health issues and allocation of scarce resources is a priority for Brazilian 
Health System.
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objeCtives: The nature and frequency of global stakeholder real world data 
(RWD) “ask” is growing and there is an impact of not having RW evidence upon 
market entry such as delayed approval, suboptimal reimbursement and unfavora-
ble re-evaluation. We aimed to assess RWD use for market access (MA) decisions in 
key global markets. Methods: Search of the HTAWatch database supplemented 
by an online search of MA stakeholders in the US, UK, Australia, and Canada 
for use of RWD to support of initial assessment, re-evaluation or coverage and 
reimbursement recommendations. Use of RWD included safety, effectiveness, 
economic or quality of life studies. We also assessed theevidence level required 
from registry to provider or patient survey data. Results: In the UK, the National 
Health Service uses real-world adherence studies to update national treatment 
guidelines and inform reimbursement. In Australia, the Pharmaceutical Benefits 
Advisory Committee is willing to delay or make temporary decisions in anticipa-
tion of RWD on a product’s clinical effectiveness or economic value message. The 
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exPlorIng tHe VarIaBIlIty BetWeen dISeaSe tyPe and tHe ProPortIon 
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accePted By Hta agencIeS
Griffiths E.A., Walsh S.C.M.
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objeCtives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £30,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To inform future submissions, we explored the 
proportion of accepted submissions by disease area and examined any variability in 
the proportion of submissions that were accepted despite the reported ICERs being 
higher than these thresholds. Methods: All HTA appraisals from January 2000 
to January 2014 from NICE, SMC, CADTH, and PBAC were included in the analysis. 
Multiple technology appraisals, vaccination programmes, requests for advice, and 
submissions for which an ICER could not be determined were excluded from analy-
sis. Appraisals were categorized by BNF disease type and the full responses were 
reviewed; the submitted ICER, recommendation, and reasoning behind the recom-
mendation were extracted. Results: Across all four agencies, 679 submissions 
met the inclusion criteria and 218 submissions included a higher than threshold 
ICER, with 62 (28%) of these accepted. The proportion of submissions with ICERs 
above the threshold that were accepted varied by disease type, ranging from 0% 
(Cardiovascular System) to 50% (Skin). This variability was largely due to the low 
number of submissions with ICERs above the threshold in 14/15 disease type cat-
egories. The remaining disease type (Malignant Disease and Immunosuppression) 
accounted for the majority (59%) of all submissions with ICERs higher than the 
threshold; 36/128 (28%) of these were accepted. Key decision drivers for acceptance 
included unmet clinical need, and condition of participation in a patient access 
or risk sharing scheme. ConClusions: A considerable proportion of submis-
sions were accepted despite ICERs above the threshold, but this proportion varied 
widely between disease types. The majority of disease types had few submissions 
reporting ICERs above the threshold, with the exception of Malignant Disease and 
Immunosuppression.
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objeCtives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £30,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To inform future submissions, we explored the 
proportion of rejected submissions by disease area and examined any variability in 
the proportion of submissions that were rejected despite the reported ICERs being 
lower than these thresholds Methods: All HTA appraisals from January 2000 to 
January 2014 from NICE, SMC, CADTH, and PBAC were included in the analysis. 
Multiple technology appraisals, vaccination programmes, requests for advice, and 
submissions for which an ICER could not be determined were excluded from analy-
sis. Appraisals were categorized by BNF disease type and the full responses were 
reviewed, with the submitted ICER, recommendation, and reasoning behind the 
recommendation extracted. Results: Across all four agencies, 679 submissions 
met the inclusion criteria and 405 submissions included a lower than threshold 
ICER, with 126 (31%) of these submissions rejected. The proportion of submissions 
rejected despite ICERs below the threshold varied by disease type. Disease types 
where a high proportion (≥ 50%) of submissions were rejected despite ICERs below 
the threshold included ‘Respiratory System’ (55% rejected), ‘Central Nervous System’ 
(55%), and ‘Nutrition and Blood’ (55%). Disease areas with a low proportion (≤ 20%) 
of rejected submissions were ‘Infections’ (19%) and ‘Eye’ (20%). Key decision drivers 
for rejection these disease types were due to high levels of uncertainty regarding 
clinical-effectiveness, and subsequent cost-effectiveness. ConClusions: The 
proportion of submissions that were rejected varied dramatically by disease type. 
In some disease types over half of submissions with an ICER below the threshold 
were not recommended largely due to non-robust economic analyses, which may 
indicate inherent underlying difficulties in these disease types in submitting a 
conclusive data package.
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IneSSS VerSuS cdr
Mills F., Poinas A.C., Siu E., Wyatt G.
Wyatt Health Management, Oakville, ON, Canada
objeCtives: To compare the positive recommendation rate and agreement 
between CDR and INESSS. Methods: In Canada, eligible non-cancer prescription 
drugs approved by Health Canada are reviewed by 2 health technology assess-
ment (HTA) agencies: the Common Drug Review (CDR) and the Institute national 
d’excellence en santé et en services sociaux (INESSS). CDR is part of the Canadian 
Agency for Drugs and Technologies in Health (CADTH), which makes reimburse-
ment recommendations that are considered by provincial and federal plans, with 
the exception of Quebec, in making their formulary coverage decisions. In Quebec 
INESSS performs HTA and issues recommendations to the Regie d’assurance mala-
die Quebec (RAMQ). Prior to INESSS, HTA in Quebec was performed by the Conseil 
du Médicaments (CdM). Using our proprietary CDR Tracker®database we examined 
the recommendations by both agencies and compared recommendation positivity 
and congruence for all drugs which have been reviewed by CDR, up to December 
31, 2013. We separately considered positive and negative recommendations by 
both agencies. Results: The overall positivity rate for CDR recommendations in 
this period was 52%, compared to 66.9% for INESSS. Of the 275 recommendations 
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objeCtives: The objective of this study was to compare the promotional strate-
gies of life style drugs (LSD) with non-lifestyle drugs (NLSD) by content analyzing 
print advertisements. Methods: 142 print advertisements were analyzed to see 
how LSD and NLSD ad messages differed with respect to rational appeals, emo-
tional appeals and readability. Mann-Whitney U test was performed to compare 
the two groups of drug advertisements with respect to the type of promotional 
claims. Descriptive statistics were computed to summarize data pertaining to 
different ad features. The dataset was composed of 64 LSD advertisements and 
78 NLSD advertisements. Inter- rater reliability was measured by Cohen’s Kappa 
for two raters and was found to be adequate for all the variables used in the 
instrument. Results: Significant differences were observed between LSD and 
NLSD ads with respect to both emotional appeals (p= 0.000) and rational appeals 
(p= 0.000) based on Mann-Whitney U test. LSD ads focused more on emotional 
appeals while NLSD ads were heavy on rational content. A logistic regression 
analysis revealed likelihood estimates for ad claims appearing in the two groups. 
Readability calculated by Gunning-Fog Index for LSD’s was 8.84 and for NLSD’s 
was 11.56. Flesch-Kincaid grade level for LSD and NLSD was found to be 7.65 
and 10.73, respectively, indicating increased complexity of language in NLSD 
ads, which was mostly reflecting of the greater use of technical scientific lan-
guage. ConClusions: The two groups of ads clearly differed with respect to 
type of content, presentation, structure and complexity as well as promotional 
strategies adopted. Rational appeals were more predictive of NLSD ad type while 
emotional appeals were predominant in LSD ads.
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oPPortunItIeS for tHe future of unIted StateS medIcal deVIce 
SurVeIllance: an analySIS of tHe joInt rePlacement regIStry (jrr) 
landScaPe In tHe unIted StateS
Pratt K.J., Song K.M., Mitchell K.
Avalere Health LLC, Washington, DC, USA
objeCtives: Annually, over 1 million people in the U.S. undergo hip or knee replace-
ments. Registries provide one mechanism to understand the benefits and risks 
of joint replacement in specific populations or care settings. Although countries 
such as Australia and Sweden have successfully established centralized JRRs, the 
U.S. has not. Avalere analyzed the diverse landscape of U.S. JRRs to determine 
the feasibility of creating one coordinated, national JRR for post-market surveil-
lance. Methods: Avalere identified JRRs in the U.S. through the International 
Consortium of Orthopaedic Registries participants’ list, PubMed searches, abstract 
reviews, and web searches. Using publicly available sources, characteristics of each 
registry were recorded in a table. Avalere assessed this data to better understand 
the feasibility of harmonizing these registry efforts. Results: In total, 25 JRRs were 
identified: 3 national, 4 state, and 18 local. Established between 1967 and 2011, the 
registries spanned 14 states with objectives including post-market surveillance, 
outcome improvement, research, provider feedback, and value-based purchasing. Of 
the 20 registries with enrollment information, 15 enrolled 1-10 hospitals, 4 enrolled 
11-50 hospitals, and 1 enrolled more than 200 hospitals. One registry collected only 
Level I data; 2 collect Levels I-II; 9 collect Levels I-III; and 2 collect Levels I-IV; 11 
registries did not have data level collection information. Registry funding sources 
were self-funded (n= 7), publicly funded (n= 1), private payer (n= 1), and a combina-
tion (n= 2). ConClusions: U.S. registries typically are established to serve the needs 
of their operating organization, which influences factors such as the registry’s mis-
sion, recruitment efforts, and data level collected. While the number of JRRs reflects 
stakeholders’ recognition of their value, the disparate (and sometimes competing) 
nature of efforts may pose challenges to the creation of a national JRR that can 
coordinate existing registries, ensure high quality data collection, and facilitate 
early surveillance to support federal regulatory needs.
HealtH care uSe & PolIcy StudIeS – Prescribing Behavior & treatment 
guidelines
PHP116
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objeCtives: Continuous, indiscriminate and excessive use of antimicrobial agents 
leads to emergence of antimicrobial-resistant organisms. Antimicrobial resistance 
substantially raises health care costs and influences patient outcomes (morbidity 
& mortality). There is a dearth of data available on appropriateness of parenteral 
antimicrobial therapy in the ICUs, especially in Indian settings. This study involves 
applying the GAAT criteria to assess the antimicrobial use. Methods: This pro-
spective observational study was carried out in the intensive care units of a public 
teaching hospital over a period of 12 weeks. All the relevant data was recorded in a 
pre-designed standardized performa and analyzed. The patients were followed for 
first 7 days of ICU stay and the changes made in the treatment regimen were care-
fully evaluated. Parenteral antimicrobial therapy was assessed for appropriateness 
using GAAT. Intravenous antimicrobial therapy was considered appropriate if two 
or more of the GAAT criteria were met. Results: 85 ICU patients’ records were 
screened during the study period. Out of total 85 patients, 44 patients were male 
while remaining 41 were females. Of these, 74 patient records were found to have 
complete data for studying GAAT criteria. The parenteral antimicrobial therapy was 
found to be appropriate in 61 patients (82%), as per GAAT criteria. ConClusions: 
Parenteral antimicrobial therapy, as per GAAT, in this study was appropriate in 82% 
of the patients. This is a preliminary study, future large scale studies should be car-
ried out over a longer period of time to draw any logical conclusion.
Canadian Agency for Drugs and Technologies in Health is funding initiatives such 
as the Canadian Platform To increase Usage of Real-world Evidence (CAPTURE) 
project in which physicians collaborate on gathering RWD to inform and improve 
standard health care practices. Finally, some US hospitals are leveraging the RWD 
they generate to optimize clinical and economic outcomes for their populations. 
Additionally, US payers are funding comparative effectiveness studies in crowded 
markets with costly assets and generic competition. ConClusions: There is a 
need to monitor HTA agencies’ use of RWD to optimize access of the right treat-
ments to the right patients. There is also a need to approach evidence generation 
in a systematic manner to differentiate assets beyond approval and initial P&R 
as well as to generate evidence only for those gaps that will impact health care 
decisions.
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eVIdence-BaSed PractIce recommendatIonS: HealtH QualIty 
ontarIo’S aPProacH
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objeCtives: As part of the Ontario Government’s health system funding reform ini-
tiative, the Evidence Development and Standards division at Health Quality Ontario 
(HQO) was tasked with developing episodes of care consisting of evidence-based, 
best practice recommendations. The HQO clinical handbooks span both medical 
and surgical conditions, in acute care and community based settings, and include 
between 25 and 100 recommendations each. The objective is to describe HQO’s 
methodology for developing evidence-based recommended best practices for epi-
sodes of care within the rapid timelines of the government mandated funding 
reform. Methods: Over a 1-year period, the method for deriving evidence-based 
recommended practices was systematically and iteratively developed by HQO clini-
cal epidemiologists in collaboration with methodologists, clinical experts and stake-
holders. Results: The resulting approach for applying evidence to best practice 
recommendations included consideration of various evidence sources and consen-
sus from expert panels which were formed for each of the clinical topics. Preference 
was given to existing Ontario Health Technology Assessment Committee (OHTAC) 
recommendations as these are developed using a decision-making framework that 
considers the clinical benefit offered by a health intervention, in addition to value 
for money; societal and ethical considerations; and economic and organizational 
feasibility. Where OHTAC recommendations did not exist, international guidelines 
were reviewed and selected based on their contextual relevance and assessment 
of their rigor of development using the AGREE II instrument. Uncertainty or con-
flict between the guidelines, or by the expert panel members, was addressed with 
systematic evaluations of the literature through rapid reviews and evidence-based 
analyses. ConClusions: While continually evolving to balance thoroughness and 
timeliness of evidence, HQO has developed a method of deriving episode of care 
recommended best practices set on an evidentiary base within a time-constrained 
government mandate.
HealtH care uSe & PolIcy StudIeS – Patient registries & Post-marketing 
Studies
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objeCtives: To assess the currently perceived benefits and barriers of post-
marketing payer-manufacturer outcomes study collaborations by US payers and 
pharmaceutical manufacturers. Methods: Regional and national US payers and 
pharmaceutical manufacturers with experience in collaborative post-marketing 
outcomes study endeavors were invited to participate in an hour-long telephone 
survey. The survey consisted of questions regarding their perceptions on the benefits 
and barriers of potential post-marketing outcomes study collaborations, as well 
as attributes of potential collaborators, studies, products or diseases that would 
be most highly valued. Descriptive statistics were used to characterize the survey 
responses. Results: A total of 12 payers and four pharmaceutical manufacturer 
representatives participated in the survey. Payers most often mentioned that the 
greatest benefit to partnering with manufacturers was the value manufacturers 
bring in terms of expertise and resources (58%). Benefits manufacturers identified 
included demonstrating consistency in outcomes data relative to randomized clini-
cal trial data and effectiveness in real-world populations. The two most commonly 
cited barriers by payers regarding participation in these post-marketing outcomes 
research collaborations included misaligned incentives (58%) and resource inten-
siveness (58%). The manufacturers felt that payers are generally wary of these types 
of collaborations due to possible perceptions of influence, and noted that payers 
are usually only willing to engage and focus on high-budget impact projects and 
collaborations. Payers’ most important consideration when selecting a pharma-
ceutical partner for outcomes studies was the willingness of the manufacturer to 
compromise and align on objectives (42%). Manufacturers agreed that alignment on 
objectives and expectations is critical for a successful partnership. ConClusions: 
As competition in the pharmaceutical marketplace increases and recent US health 
care reform moves forward, payer-manufacturer post-marketing outcomes research 
collaborations will be increasingly critical as a demonstration of value to all stake-
holders.
PHP114
are PromotIonal StrategIeS of lIfeStyle drugS dIfferent from non-
lIfeStyle drugS? a content analySIS of dtc PrInt medIa
Shanbhag P.1, Kapratwar A.1, Nayak R.2
1St. Johns University, Fresh Meadows, NY, USA, 2St. John’s University, Jamaica, NY, USA
